Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 3/20 | 0.46 |
| ▸ | MAOB | P27338 | 1/20 | 0.43 |
| ▸ | IDO1 | P14902 | 2/20 | 0.41 |
| ▸ | AGXT | P21549 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.40 |
| ▸ | GSK3B | P49841 | 1/20 | 0.40 |
| ▸ | BACE1 | P56817 | 1/20 | 0.40 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | POLQ | O75417 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.39 |
| ▸ | HTR2A | P28223 | 1/20 | 0.38 |
| ▸ | TAS2R14 | Q9NYV8 | 1/20 | 0.37 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17157335 | 0.85 | MAOB (0.45) | RIPK1MAOBIDO1AGXTALDH1A1 | |
| SCHEMBL22235800 | 0.85 | PYCR1 (0.43) | TDP1P2RX7 | |
| SCHEMBL31173162 | 0.85 | PYCR1 (0.43) | TDP1P2RX7 | |
| SCHEMBL19030893 | 0.85 | POLQ (0.43) | ALDH1A1POLQKDM4EHTR2A | |
| SCHEMBL8572100 | 0.83 | RIPK1 (0.50) | RIPK1MAOBIDO1AGXTALDH1A1 | |
| SCHEMBL15271084 | 0.81 | RIPK1 (0.49) | RIPK1TRPM8 | |
| SCHEMBL1668464 | 0.81 | ALDH1A1 (0.45) | RIPK1MAOBALDH1A1POLQKDM4E | |
| SCHEMBL1399311 | 0.77 | TDP1 (0.56) | ALDH1A1TDP1HTTKDM4E | |
| SCHEMBL3967997 | 0.77 | SMN1; SMN2 (0.48) | RIPK1MAOBIDO1AGXTALDH1A1 | |
| SCHEMBL29836179 | 0.77 | SMN1; SMN2 (0.48) | RIPK1MAOBIDO1AGXTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1981877-B1 | N-HYDROXYACRYLAMIDE COMPOUNDS | ASTELLAS PHARMA INC (JP) | 2012-04-18 | — | — | EP | disclosed |
| US-7750155-B2 | Pyrazinyl hydroxyacrylamide compounds having an inhibitory effect on the activity of histone deacetylase | ASTELLAS PHARMA INC. (JP) | 2010-07-06 | — | — | US | disclosed |
| US-20090215817-A1 | Novel Triazolopyridine Compounds for the Treatment of Inflammation | PFIZER INC | 2009-08-27 | — | — | US | disclosed |
| US-20090209577-A1 | Novel Triazolopyridine Compounds | PFIZER INC. (US) | 2009-08-20 | — | — | US | disclosed |
| US-20090054465-A1 | N-HYDROXYACRYLAMIDE COMPOUNDS | ASTELLA PHARMA INC. (JP) | 2009-02-26 | — | — | US | disclosed |
| EP-1981877-A1 | N-HYDROXYACRYLAMIDE COMPOUNDS | Astellas Pharma Inc. (JP) | 2008-10-22 | — | — | EP | disclosed |
| WO-2007091703-A1 | N-HYDROXYACRYLAMIDE COMPOUNDS | ASTELLAS PHARMA INC. (JP) | 2007-08-16 | — | — | WO | disclosed |
| EP-1786811-A2 | TRIAZOLOPYRIDINE COMPOUNDS | Pharmacia & Upjohn Company LLC (US) | 2007-05-23 | — | — | EP | disclosed |
| EP-1781655-A2 | TRIAZOLOPYRIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF INFLAMMATION | Pharmacia & Upjohn Company LLC (US) | 2007-05-09 | — | — | EP | disclosed |
| WO-2006018735-A2 | TRIAZOLOPYRIDINE COMPOUNDS | PHARMACIA & UPJOHN COMPANY LLC (US) | 2006-02-23 | — | — | WO | disclosed |
| WO-2006018727-A2 | TRIAZOLOPYRIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF INFLAMMATION | PHARMACIA & UPJOHN COMPANY LLC (US) | 2006-02-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090054465-A1 | N-HYDROXYACRYLAMIDE COMPOUNDS | HDAC1, HDAC6, HDAC5 | RIPK1 4361/4885MAOB 1645/4885IDO1 2064/4885 |
| US-20090209577-A1 | Novel Triazolopyridine Compounds | MAP3K2, MAP3K5, MAP3K9 | RIPK1 526/4885MAOB 1008/4885IDO1 1182/4885 |
| US-20090215817-A1 | Novel Triazolopyridine Compounds for the Treatment of Inflammation | TNF, MAP3K2, MAP3K5 | RIPK1 436/4885MAOB 1395/4885IDO1 741/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.